Skip to content

Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses

Investigation of Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06175078
Enrollment
200
Registered
2023-12-18
Start date
2024-04-30
Completion date
2029-04-30
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Masses

Keywords

Ultrasound Imaging 3D, Spectroscopy

Brief summary

The purpose of the study is to test the hypothesis that quantitative ultrasound techniques including spectroscopy may be used as a non-invasive biomarker for characterization of suspected breast cancers. The main goal is to select and identify an optimal set of quantitative ultrasound parameters that can be used, non-invasively, to characterize suspected breast cancers, as identified based on the histopathology reports on core biopsy specimens, surgery reports, or radiology reports. Primary endpoint will correlate quantitative ultrasound parameters to the histopathological properties, as determined from pathology reports on core biopsy specimens, surgery reports, or radiology reports. The secondary endpoint in this study will include correlating the results of ultrasound-based breast cancer characterization with 2 and 5-years clinical outcomes.

Detailed description

This project is an observational/early validation study in human subjects that will use ultrasound imaging and spectroscopy to characterize suspected breast cancers. Patients will be imaged with ultrasound, and the acquired data will be analyzed using quantitative ultrasound techniques, in conjunction with textural analysis on generated parametric images. Results of quantitative ultrasound data analysis for these breast lumps will be compared to and correlated with histopathological characteristics from pathology reports on core biopsy specimens, surgery reports, or radiology reports.

Interventions

Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.

Sponsors

Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Women or men with suspected breast cancer 2. Patients should have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

1. Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering in the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration. 2. Receiving any other investigational agents. 3. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

Design outcomes

Primary

MeasureTime frameDescription
Correlation of quantitative ultrasound parameters to the histopathological properties of suspected breast cancer tissues.Up to 2 yearsAs a primary endpoint, correlate changes in ultrasound backscatter parameters obtained using spectroscopic techniques, in conjunction with textural analysis on generated parametric images, to the histopathological characteristics from pathology reports on core biopsy specimens, surgery reports, or radiology reports.

Secondary

MeasureTime frameDescription
Correlating the results of ultrasound-based breast cancer characterization to clinical outcomes.Up to 5 yearsThe secondary endpoint in this study will include correlating the results of ultrasound-based breast cancer characterization with 2 and 5-years clinical outcomes.

Countries

Canada

Contacts

Primary ContactGregory J Czarnota, PhD, MD
Gregory.Czarnota@sunnybrook.ca(416) 480-5329

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026